Technology

TOP
technology

Approach
pipeline
catheter
Regenerative Therapeutics Discovery

Cuorips’ Approach to Regenerative Medicine

Beginning with cardiovascular care, Cuorips is actively advancing R&D to expand the application of regenerative medicine to various organs across the body.

Pipeline

catheter

Our Solution
Overcoming the Key Barrier
Myocardial Infarction
The Ischemic Border Zone

Regenerative Medicine Drug Discovery

Regenerative Medicine for a Broad Patient Base: Pioneering the Future of Cell-Free Therapies.

Cuorips aims to be a comprehensive platform leader, extending the benefits of regenerative medicine beyond specialized cell therapies to a broader patient population. The key to this vision lies in our small molecule programs (endogenous regenerative factor inducers).This approach utilizes small molecule compounds—delivered as standard pharmaceuticals—to activate the body’s intrinsic repair mechanisms, functioning as a booster for natural tissue regeneration. By leveraging a dual-engine strategy that pairs highly specialized cell therapies for severe, late-stage conditions with accessible small molecule treatments for early-stage intervention, we ensure that regenerative medicine reaches patients at every stage of need.
- Cell Therapy (Specialized Surgical Care) ➔ Late-stage severe conditions
- Endogenous Regenerative Factor Inducers (Standard Pharmaceuticals) ➔ Early-stage intervention & broader patient populations

Mechanism of Endogenous Regenerative Factor Induction and Advanced Formulation Technology

YS-1301

YS-1301 is a proprietary small molecule compound engineered to serve as a precise "key" that unlocks the body's intrinsic healing and regenerative capabilities.Our bodies possess a natural cellular network that dilates blood vessels, suppresses inflammation, and repairs or protects damaged tissues—a mechanism controlled by the IP receptor (the "lock"). YS-1301 is designed to fit this receptor perfectly, functioning as a powerful booster to activate endogenous tissue repair. Because YS-1301 is highly selective, minimizing interactions with unintended targets, it is engineered to efficiently elicit targeted therapeutic effects while reducing the risk of unwanted side effects.
YS-1402

While YS-1301 serves as the "key" to trigger the regenerative switch, YS-1402 is an innovative sustained-release formulation engineered to continuously deliver the active compound within the body over a period of approximately four weeks.Rather than releasing the dose all at once, this formulation ensures a gradual, steady supply of the therapeutic agent. This advanced drug delivery mechanism is designed to provide long-term, uninterrupted support to the body’s intrinsic healing pathways from a single administration.